In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fresenius Kabi, Sanofi settle oxaliplatin litigation

Executive Summary

Settling ongoing patent litigation, Fresenius Kabi AG and its US division APP Pharmaceuticals Inc., along with other Fresenius Kabi divisions, have been granted a license to market generic versions of Sanofi-Aventis' Eloxatin (oxaliplatin) for Stage III colon cancer. The fight began in 2007 when APP and Fresenius filed an ANDA for their version of oxaliplatin, and Sanofi argued that the product would infringe on existing patents. APP and Fresenius will market 50mg, 100mg, 5mg/mL, 10mL, and 20mL vials by August 9, 2012.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies